Overview of Dr. McKiernan
Dr. James McKiernan is an urologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, NewYork-Presbyterian/Columbia University Irving Medical Center, and NewYork-Presbyterian/Allen Hospital. He received his medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 24 years. He is one of 188 doctors at New York-Presbyterian Hospital and one of 7 doctors at NewYork-Presbyterian/Allen Hospital who specialize in Urology. He has more than 100 publications and over 500 citings.
Office
161 Fort Washington Ave
New York, NY 10032Fax+1 212-305-0129
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Residency, Urology, 1995 - 1999
- New York Presbyterian Hospital (Columbia Campus)Residency, Surgery, 1993 - 1995
- Columbia University Vagelos College of Physicians and SurgeonsClass of 1993
- Johns Hopkins UniversityB.A., Biology, 1989
Certifications & Licensure
- FL State Medical License 2021 - Present
- NJ State Medical License 2021 - 2025
- NY State Medical License 1996 - 2025
- American Board of Urology Urology
Awards, Honors, & Recognition
- Top Doctors: New York Metro Area Castle Connolly, 2007-2014
- New York Magazine: Top Doctors Castle Connolly, 2012, 2014
- Humanism in Medicine Award Arnold P. Gold Foundation, 2013
- Join now to see all
Clinical Trials
- Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer Start of enrollment: 2007 Dec 01
- Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer Start of enrollment: 2014 Mar 01
- Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer Start of enrollment: 2014 Apr 09
- Join now to see all
Publications & Presentations
PubMed
- 111 citationsModelling bladder cancer in mice: opportunities and challengesTakashi Kobayashi, Tomasz Owczarek, James M. McKiernan, Cory Abate-Shen
Nature Reviews. Cancer. 2015-01-01 - 13 citationsThe effect of fibrin clot inhibitors on the immunomodulatory efficacy of Bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer.Michael J Lipsky, Gina M. Badalato, Piruz Motamedinia, Greg Hruby, James M. McKiernan
Urology. 2013-06-01 - 165 citationsA First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder CancerJames M. Burke, Donald L. Lamm, Maxwell V. Meng, John Nemunaitis, Joseph J. Stephenson
The Journal of Urology. 2012-12-01
Journal Articles
- Impact of synchronous metastasis distribution on cancer-specific survival in renal cell carcinoma after radical nephrectomy with tumor thrombectomyTilki D, Hu B, Nguyen HG, Dall'Era MA, Bertini R, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner..., Urol, 7/22/2014
- Cost-effectiveness of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancerStevenson SM, Danzig MR, Ghandour RA, Deibert CM, Joel Decastro G, Benson MC, McKiernan JM, Urol Oncol, 7/3/2014
- Phase II Trial of Intravesical Nanoparticle Albumin-Bound (nab-) Paclitaxel for the Treatment of Non-Muscle Invasive Urothelial Carcinoma of the Bladder after BCG Trea...McKiernan JM, Holder DD, Ghandour RA, Barlow LJ, Ahn JJ, Kates M, Badalato GM, Roychoudhury A, Decastro GJ, Benson MC, J Urol, 7/1/2014
- Join now to see all
Books/Book Chapters
Authored Content
- Is Imperative Partial Nephrectomy Feasible for Kidney Cancer with Venous Thrombus Involvement? Outcomes of 42 Cases and Matched Pair Analysis with a Large Radical Nephrectomy CohortMay 2018
- Is Imperative Partial Nephrectomy Feasible for Kidney Cancer with Venous Thrombus Involvement? Outcomes of 42 Cases and Matched Pair Analysis with a Large Radical Nephrectomy CohortMay 2018
- Is Imperative Partial Nephrectomy Feasible for Kidney Cancer with Venous Thrombus Involvement? Outcomes of 42 Cases and Matched Pair Analysis with a Large Radical Nephrectomy CohortMay 2018
Press Mentions
- New Treatment Options Emerging for Patients with Refractory NMIBCMay 13th, 2022
- Bio-Techne Announces Publication of ExoDx Prostate Test Study in Patients with Prior Negative Prostate BiopsySeptember 23rd, 2020
- miR Scientific Announces Validation of Its Urine Based, Non-Invasive Prostate Cancer Test Published in the Journal of UrologyAugust 10th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: